Cipla Ltd
NSE:CIPLA

Watchlist Manager
Cipla Ltd Logo
Cipla Ltd
NSE:CIPLA
Watchlist
Price: 1 442.2 INR -2.88% Market Closed
Market Cap: 1.2T INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CIPLA stock under the Base Case scenario is 1 505.1 INR. Compared to the current market price of 1 442.2 INR, Cipla Ltd is Undervalued by 4%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CIPLA Relative Value
Base Case
1 505.1 INR
Undervaluation 4%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.3
P/S
P/S
Price to Sales
4.3
vs History
15
vs Industry
27
Median 3Y
4
Median 5Y
3.7
Industry
2.4
Forward
4.1
More Details
23.3
P/E
P/E
Price to Earnings
23.3
vs History
90
vs Industry
19
Median 3Y
29
Median 5Y
29.5
Industry
20.8
Forward
23.4
More Details
25.9
P/OCF
P/OCF
Price to OCF
25.9
vs History
31
vs Industry
15
Median 3Y
26.6
Median 5Y
24.1
Industry
15.4
More Details
49.6
P/FCFE
P/FCFE
Price to FCFE
49.6
vs History
57
vs Industry
11
Median 3Y
52.9
Median 5Y
52.5
Industry
22.8
More Details
4.1
P/B
P/B
Price to Book Value
4.1
vs History
23
vs Industry
17
Median 3Y
4.1
Median 5Y
3.9
Industry
2
More Details
4
EV/S
EV/S
Enterprise Value to Sales
4
vs History
17
vs Industry
29
Median 3Y
3.7
Median 5Y
3.5
Industry
2.5
Forward
3.8
More Details
5.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.9
vs History
30
vs Industry
33
Median 3Y
6.1
Median 5Y
5.7
Industry
4.9
More Details
15.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
15.7
vs History
50
vs Industry
22
Median 3Y
16.7
Median 5Y
16.3
Industry
12.7
Forward
14.9
More Details
18.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
18.6
vs History
80
vs Industry
22
Median 3Y
20.8
Median 5Y
20.9
Industry
15.8
Forward
17.2
More Details
24
EV/OCF
EV/OCF
Enterprise Value to OCF
24
vs History
31
vs Industry
17
Median 3Y
24.8
Median 5Y
22.4
Industry
14
More Details
36.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
36.6
vs History
28
vs Industry
13
Median 3Y
37.6
Median 5Y
29.8
Industry
18.3
More Details
4.6
EV/IC
EV/IC
Enterprise Value to IC
4.6
vs History
19
vs Industry
16
Median 3Y
4.2
Median 5Y
3.9
Industry
1.7
More Details

Multiples Across Competitors

CIPLA Competitors Multiples
Cipla Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Cipla Ltd
NSE:CIPLA
1.2T INR 4.3 23.3 15.7 18.6
US
Eli Lilly and Co
NYSE:LLY
779.4B USD 17.3 73.6 42.8 47.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
394B USD 4.4 28 13.1 17.2
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 7.2 20.8 13.7 15.6
CH
Roche Holding AG
SIX:ROG
236.5B CHF 4 20.6 11.5 13.6
UK
AstraZeneca PLC
LSE:AZN
177B GBP 4.2 32.6 126.9 193.9
US
Merck & Co Inc
NYSE:MRK
225.9B USD 3.5 13.2 8.9 10.5
CH
Novartis AG
SIX:NOVN
199.7B CHF 4.4 19 11.5 14.7
IE
Endo International PLC
LSE:0Y5F
167.6B USD 72.3 -57.3 267.5 670.8
US
Pfizer Inc
NYSE:PFE
142.8B USD 2.2 17.8 8.5 12.1
P/E Multiple
Earnings Growth PEG
IN
Cipla Ltd
NSE:CIPLA
Average P/E: 27.7
23.3
10%
2.3
US
Eli Lilly and Co
NYSE:LLY
73.6
49%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
28
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
20.8
19%
1.1
CH
Roche Holding AG
SIX:ROG
20.6
16%
1.3
UK
AstraZeneca PLC
LSE:AZN
32.6
36%
0.9
US
Merck & Co Inc
NYSE:MRK
13.2
18%
0.7
CH
Novartis AG
SIX:NOVN
19
16%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -57.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.8
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Cipla Ltd
NSE:CIPLA
Average EV/EBITDA: 397
15.7
7%
2.2
US
Eli Lilly and Co
NYSE:LLY
42.8
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.1
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
15%
0.9
CH
Roche Holding AG
SIX:ROG
11.5
8%
1.4
UK
AstraZeneca PLC
LSE:AZN
126.9
9%
14.1
US
Merck & Co Inc
NYSE:MRK
8.9
9%
1
CH
Novartis AG
SIX:NOVN
11.5
5%
2.3
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.5
3%
2.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Cipla Ltd
NSE:CIPLA
Average EV/EBIT: 1 701.5
18.6
7%
2.7
US
Eli Lilly and Co
NYSE:LLY
47.2
33%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.2
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
15.6
16%
1
CH
Roche Holding AG
SIX:ROG
13.6
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
193.9
21%
9.2
US
Merck & Co Inc
NYSE:MRK
10.5
12%
0.9
CH
Novartis AG
SIX:NOVN
14.7
8%
1.8
IE
E
Endo International PLC
LSE:0Y5F
670.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.1
10%
1.2

See Also

Summary
CIPLA intrinsic value, competitors valuation, and company profile.
DCF Valuation
CIPLA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CIPLA stock valuation using valuation multiples.
Wall Street Estimates
CIPLA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CIPLA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 242,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.